Imfinzi+Imjudo shows significant PFS improvement in early liver cancer trial
Portfolio teams should consider the implications of this combination therapy for future treatment guidelines and market access strategies.
Phase III
Oncology / Liver Cancer
Primary Endpoint
PFS
Status
Positive
Sponsor
Oncology
Signal Score
8.4
Signal assessment
Signal strength
high
Confidence level
high
Strategic implication
Portfolio teams should consider the implications of this combination therapy for future treatment guidelines and market access strategies.
Why it matters
Portfolio teams should consider the implications of this combination therapy for future treatment guidelines and market access strategies.
What changed
Trial Update
Analysis
The EMERALD-3 Phase III trial demonstrated a statistically significant improvement in progression-free survival for Imfinzi plus Imjudo in patients with unresectable liver cancer.
Portfolio teams should consider the implications of this combination therapy for future treatment guidelines and market access strategies.
Monitor regulatory submissions and potential market launch timelines following these trial results.
Related companies & assets
Sources & Humanexa intelligence
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.